You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTetrabenazine
Accession NumberDB04844
TypeSmall Molecule
GroupsApproved
DescriptionA drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
Structure
Thumb
Synonyms
1,2,4,6,7,11b-hexahydro-3-Isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one
2-oxo-3-Isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bh-benzo[a]quinolizine
2-oxo-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-benzoquinolizine
TBZ
Tetra benazin
Tetrabenazina
Tetrabenazinum
Tetrabenzaine
Tetrabenzine
External Identifiers
  • Ro 1-9569
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nitomantablet25 mgoralValeant Canada Lp Valeant Canada S.E.C.1996-12-09Not applicableCanada
PMS-tetrabenazinetablet25 mgoralPharmascience Inc2013-02-26Not applicableCanada
Tetrabenazinetablet12.5 mg/1oralOceanside Pharmaceuticals2015-07-20Not applicableUs
Tetrabenazinetablet25 mg/1oralOceanside Pharmaceuticals2015-07-20Not applicableUs
Tetrabenazine Tabletstablet25 mgoralSterimax Inc2013-08-29Not applicableCanada
Xenazinetablet12.5 mg/1oralLundbeck Inc.2008-11-24Not applicableUs
Xenazinetablet25 mg/1oralLundbeck Inc.2008-11-24Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tetrabenazinetablet25 mgoralApotex Inc2013-11-01Not applicableCanada
Tetrabenazinetablet, coated12.5 mg/1oralCamber Pharmaceuticals, Inc.2015-08-17Not applicableUs
Tetrabenazinetablet, coated25 mg/1oralCamber Pharmaceuticals, Inc.2015-08-17Not applicableUs
Tetrabenazinetablet25 mg/1oralSun Pharma Global FZE2015-08-17Not applicableUs
Tetrabenazinetablet12.5 mg/1oralSun Pharma Global FZE2015-08-17Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
RubigenNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIZ9O08YRN8O
CAS number58-46-8
WeightAverage: 317.4226
Monoisotopic: 317.199093735
Chemical FormulaC19H27NO3
InChI KeyInChIKey=MKJIEFSOBYUXJB-UHFFFAOYSA-N
InChI
InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3
IUPAC Name
9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-one
SMILES
COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetrahydroisoquinolines. These are tetrahydrogenated isoquinoline derivatives.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassTetrahydroisoquinolines
Sub ClassNot Available
Direct ParentTetrahydroisoquinolines
Alternative Parents
Substituents
  • Tetrahydroisoquinoline
  • Anisole
  • Aralkylamine
  • Piperidinone
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Cyclic ketone
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationTreatment of hyperkinetic movement disorders like chorea in Huntington's disease, hemiballismus, senile chorea, Tourette syndrome and other tic disorders, and tardive dyskinesia
PharmacodynamicsProlongation of the QTc interval has been observed at doses of 50 mg. In rats, it has been observed that tetrabenazine or its metabolites bind to melanin-containing tissues such as the eyes and skin. After a single oral dose of radiolabeled tetrabenazine, radioactivity was still detected in eye and fur at 21 days post dosing.
Mechanism of actionTetrabenazine is a reversible human vesicular monoamine transporter type 2 inhibitor (Ki = 100 nM). It acts within the basal ganglia and promotes depletion of monoamine neurotransmitters serotonin, norepinephrine, and dopamine from stores. It also decreases uptake into synaptic vesicles. Dopamine is required for fine motor movement, so the inhibition of its transmission is efficacious for hyperkinetic movement. Tetrabenazine exhibits weak in vitro binding affinity at the dopamine D2 receptor (Ki = 2100 nM).
Related Articles
AbsorptionFollowing oral administration of tetrabenazine, the extent of absorption is at least 75%. After single oral doses ranging from 12.5 to 50 mg, plasma concentrations of tetrabenazine are generally below the limit of detection because of the rapid and extensive hepatic metabolism of tetrabenazine. Food does not affect the absorption of tetrabenazine. Cmax, oral = 4.8 ng/mL in HD or tardive dyskinesia patients; Tmax, oral = 69 min in HD or tardive dyskinesia patients
Volume of distribution

Steady State, IV, in HD or tardive dyskinesia patients: 385L.
Tetrabenazine is rapidly distributed to the brain following IV injection. The site with the highest binding is the striatum, while the lowest binding was observed in the cortex.

Protein bindingTetrabenazine = 82 - 88%; α-HTBZ = 60 - 68%; β-HTBZ = 59 - 63%.
Metabolism

Tetrabenazine is hepatically metabolized. Carbonyl reductase in the liver is responsible for the formation of two major active metabolites: α-dihydrotetrabenazine (α-HTBZ) and β-dihydrotetrabenazine (β-HTBZ). α-HTBZ is further metabolized into 9-desmethyl-α-DHTBZ, a minor metabolite by CYP2D6 and with some contribution of CYP1A2. β-HTBZ is metabolized to another major circulating metabolite, 9-desmethyl-β-DHTBZ, by CYP2D6. The Tmax of this metabolite is 2 hours post-administration of tetrabenazine.

SubstrateEnzymesProduct
Tetrabenazine
alpha-dihydrotetrabenazineDetails
Tetrabenazine
Not Available
b-dihydrotetrabenazineDetails
Route of eliminationAfter oral administration, tetrabenazine is extensively hepatically metabolized, and the metabolites are primarily renally eliminated (75%). Tetrabenazine is also cleared fecally (7% to 16%). Unchanged tetrabenazine has not been found in human urine. Urinary excretion of α-HTBZ or β-HTBZ (the major metabolites) accounted for less than 10% of the administered dose.
Half lifeα-HTBZ = 7 hours; β-HTBZ = 5 hours; 9-desmethyl-β-DHTBZ = 12 hours.
Clearance

IV, 1.67 L/min in HD or tardive dyskinesia patients

ToxicityDose-limiting adverse effects are sedation, parkinsonism, akathsia, and depression. LD50 oral, mouse: 550 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.9639
Caco-2 permeable+0.8608
P-glycoprotein substrateSubstrate0.7819
P-glycoprotein inhibitor IInhibitor0.8908
P-glycoprotein inhibitor IIInhibitor0.7631
Renal organic cation transporterInhibitor0.6484
CYP450 2C9 substrateNon-substrate0.8444
CYP450 2D6 substrateSubstrate0.6448
CYP450 3A4 substrateSubstrate0.8091
CYP450 1A2 substrateNon-inhibitor0.7482
CYP450 2C9 inhibitorNon-inhibitor0.9042
CYP450 2D6 inhibitorInhibitor0.7084
CYP450 2C19 inhibitorNon-inhibitor0.8191
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8718
Ames testNon AMES toxic0.6674
CarcinogenicityNon-carcinogens0.9083
BiodegradationNot ready biodegradable0.9974
Rat acute toxicity2.8540 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6451
hERG inhibition (predictor II)Inhibitor0.7524
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral25 mg
Tabletoral12.5 mg/1
Tabletoral25 mg/1
Tablet, coatedoral12.5 mg/1
Tablet, coatedoral25 mg/1
Prices
Unit descriptionCostUnit
Xenazine 25 mg tablet74.57USD tablet
Xenazine 12.5 mg tablet37.29USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point126 °CMSDS
water solubilitySparingly solubleFDA label
pKa6.51FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.361 mg/mLALOGPS
logP3.23ALOGPS
logP3.4ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)18.24ChemAxon
pKa (Strongest Basic)7.41ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area38.77 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity91.31 m3·mol-1ChemAxon
Polarizability36.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Michael James Rishel, Kande Kankananamalage Dayarathna Amarasinghe, Sean Richard Dinn, Bruce Fletcher Johnson, “METHOD FOR MAKING TETRABENAZINE COMPOUNDS.” U.S. Patent US20080306267, issued December 11, 2008.

US20080306267
General References
  1. Jankovic J, Beach J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb;48(2):358-62. [PubMed:9040721 ]
  2. Guay DR: Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010 Aug;8(4):331-73. doi: 10.1016/j.amjopharm.2010.08.006. [PubMed:20869622 ]
External Links
ATC CodesN07XX06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (269 KB)
MSDSDownload (79.6 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tetrabenazine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AbirateroneThe metabolism of Tetrabenazine can be decreased when combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Aceprometazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Acetophenazine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Tetrabenazine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tetrabenazine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tetrabenazine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tetrabenazine.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Tetrabenazine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tetrabenazine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tetrabenazine.
AmantadineAmantadine may increase the QTc-prolonging activities of Tetrabenazine.
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Tetrabenazine.
AmisulprideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tetrabenazine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tetrabenazine.
AmoxapineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Amperozide.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Tetrabenazine.
ApomorphineApomorphine may increase the QTc-prolonging activities of Tetrabenazine.
ArformoterolArformoterol may increase the QTc-prolonging activities of Tetrabenazine.
AripiprazoleThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Aripiprazole.
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Tetrabenazine.
ArtemetherTetrabenazine may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Tetrabenazine.
AsenapineTetrabenazine may increase the QTc-prolonging activities of Asenapine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Tetrabenazine.
AtomoxetineThe metabolism of Tetrabenazine can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Azaperone.
AzelastineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tetrabenazine.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Tetrabenazine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Tetrabenazine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Tetrabenazine.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Tetrabenazine.
BenmoxinThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Benmoxin.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tetrabenazine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tetrabenazine.
BetaxololThe metabolism of Tetrabenazine can be decreased when combined with Betaxolol.
BifeprunoxThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Bifeprunox.
BortezomibBortezomib may increase the QTc-prolonging activities of Tetrabenazine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.
BrimonidineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrabenazine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tetrabenazine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Tetrabenazine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tetrabenazine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tetrabenazine.
BupropionThe serum concentration of Tetrabenazine can be increased when it is combined with Bupropion.
BuserelinBuserelin may increase the QTc-prolonging activities of Tetrabenazine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetrabenazine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tetrabenazine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Tetrabenazine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Tetrabenazine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Tetrabenazine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Tetrabenazine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tetrabenazine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tetrabenazine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tetrabenazine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tetrabenazine.
CariprazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tetrabenazine.
CaroxazoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Caroxazone.
CelecoxibThe metabolism of Tetrabenazine can be decreased when combined with Celecoxib.
CeritinibCeritinib may increase the QTc-prolonging activities of Tetrabenazine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tetrabenazine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tetrabenazine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tetrabenazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Tetrabenazine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tetrabenazine.
ChloroquineChloroquine may increase the QTc-prolonging activities of Tetrabenazine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetrabenazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Chlorpromazine.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Tetrabenazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tetrabenazine.
CholecalciferolThe metabolism of Tetrabenazine can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Tetrabenazine can be decreased when combined with Cimetidine.
CinacalcetThe serum concentration of Tetrabenazine can be increased when it is combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tetrabenazine.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Tetrabenazine.
CisaprideCisapride may increase the QTc-prolonging activities of Tetrabenazine.
CitalopramCitalopram may increase the QTc-prolonging activities of Tetrabenazine.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Tetrabenazine.
ClemastineThe metabolism of Tetrabenazine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Tetrabenazine.
ClobazamThe metabolism of Tetrabenazine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Tetrabenazine.
ClomipramineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Clomipramine.
ClomipramineThe metabolism of Tetrabenazine can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Tetrabenazine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tetrabenazine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetrabenazine.
ClotrimazoleThe metabolism of Tetrabenazine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Clozapine.
ClozapineClozapine may increase the QTc-prolonging activities of Tetrabenazine.
CobicistatThe serum concentration of Tetrabenazine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tetrabenazine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tetrabenazine.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Tetrabenazine.
CyamemazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Tetrabenazine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrabenazine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tetrabenazine.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Tetrabenazine.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tetrabenazine.
DapiprazoleThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Dapoxetine.
DarifenacinThe metabolism of Tetrabenazine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Tetrabenazine can be increased when it is combined with Darunavir.
DasatinibDasatinib may increase the QTc-prolonging activities of Tetrabenazine.
DegarelixDegarelix may increase the QTc-prolonging activities of Tetrabenazine.
DelavirdineThe serum concentration of Tetrabenazine can be increased when it is combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Tetrabenazine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tetrabenazine.
DesipramineThe metabolism of Tetrabenazine can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tetrabenazine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Tetrabenazine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrabenazine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tetrabenazine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tetrabenazine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tetrabenazine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tetrabenazine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tetrabenazine.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Tetrabenazine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetrabenazine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tetrabenazine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetrabenazine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tetrabenazine.
DiphenhydramineThe metabolism of Tetrabenazine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tetrabenazine.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Tetrabenazine.
DofetilideDofetilide may increase the QTc-prolonging activities of Tetrabenazine.
DolasetronDolasetron may increase the QTc-prolonging activities of Tetrabenazine.
DomperidoneDomperidone may increase the QTc-prolonging activities of Tetrabenazine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Tetrabenazine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Tetrabenazine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.
DoxylamineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Tetrabenazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.
DronedaroneTetrabenazine may increase the QTc-prolonging activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Droperidol.
DroperidolDroperidol may increase the QTc-prolonging activities of Tetrabenazine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tetrabenazine.
DuloxetineThe metabolism of Tetrabenazine can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrabenazine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Tetrabenazine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Tetrabenazine.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tetrabenazine.
EliglustatTetrabenazine may increase the QTc-prolonging activities of Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tetrabenazine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Tetrabenazine.
EribulinEribulin may increase the QTc-prolonging activities of Tetrabenazine.
ErythromycinErythromycin may increase the QTc-prolonging activities of Tetrabenazine.
EscitalopramEscitalopram may increase the QTc-prolonging activities of Tetrabenazine.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tetrabenazine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tetrabenazine.
EthanolTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Tetrabenazine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrabenazine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetrabenazine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tetrabenazine.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetrabenazine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tetrabenazine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tetrabenazine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Tetrabenazine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Tetrabenazine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Tetrabenazine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrabenazine.
EtoperidoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tetrabenazine.
EzogabineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Tetrabenazine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Tetrabenazine.
FencamfamineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetrabenazine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Tetrabenazine.
FingolimodFingolimod may increase the QTc-prolonging activities of Tetrabenazine.
FlecainideFlecainide may increase the QTc-prolonging activities of Tetrabenazine.
FlibanserinThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Flibanserin.
FluconazoleFluconazole may increase the QTc-prolonging activities of Tetrabenazine.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetrabenazine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tetrabenazine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tetrabenazine.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Tetrabenazine.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Tetrabenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tetrabenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tetrabenazine.
FluvoxamineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Tetrabenazine can be decreased when combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Tetrabenazine.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Tetrabenazine.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Tetrabenazine.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tetrabenazine.
FurazolidoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Furazolidone.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetrabenazine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with gabapentin enacarbil.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Tetrabenazine.
GalantamineGalantamine may increase the QTc-prolonging activities of Tetrabenazine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tetrabenazine.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Tetrabenazine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Tetrabenazine.
GoserelinGoserelin may increase the QTc-prolonging activities of Tetrabenazine.
GranisetronGranisetron may increase the QTc-prolonging activities of Tetrabenazine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tetrabenazine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Tetrabenazine.
HaloperidolThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Haloperidol.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Tetrabenazine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tetrabenazine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tetrabenazine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tetrabenazine.
HistrelinHistrelin may increase the QTc-prolonging activities of Tetrabenazine.
HydracarbazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Hydracarbazine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tetrabenazine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrabenazine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.
HydroxyzineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Tetrabenazine.
IbutilideIbutilide may increase the QTc-prolonging activities of Tetrabenazine.
IloperidoneTetrabenazine may increase the QTc-prolonging activities of Iloperidone.
ImipramineThe metabolism of Tetrabenazine can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Imipramine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Tetrabenazine.
IndalpineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Indalpine.
IndapamideIndapamide may increase the QTc-prolonging activities of Tetrabenazine.
IndinavirThe metabolism of Tetrabenazine can be decreased when combined with Indinavir.
IproclozideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Iproclozide.
IproniazidThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Iproniazid.
IsocarboxazidThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tetrabenazine.
IsoniazidThe metabolism of Tetrabenazine can be decreased when combined with Isoniazid.
IsradipineIsradipine may increase the QTc-prolonging activities of Tetrabenazine.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Tetrabenazine.
IvabradineIvabradine may increase the QTc-prolonging activities of Tetrabenazine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetrabenazine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tetrabenazine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tetrabenazine.
KetoconazoleThe metabolism of Tetrabenazine can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetrabenazine.
LapatinibLapatinib may increase the QTc-prolonging activities of Tetrabenazine.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Tetrabenazine.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Tetrabenazine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tetrabenazine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tetrabenazine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Tetrabenazine.
LevocetirizineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Tetrabenazine.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Tetrabenazine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tetrabenazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tetrabenazine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tetrabenazine.
LithiumThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Tetrabenazine.
LopinavirLopinavir may increase the QTc-prolonging activities of Tetrabenazine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tetrabenazine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tetrabenazine.
LorcaserinThe metabolism of Tetrabenazine can be decreased when combined with Lorcaserin.
LoxapineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lu AA21004.
LumefantrineTetrabenazine may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tetrabenazine.
MebanazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Mebanazine.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Tetrabenazine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Tetrabenazine.
MefloquineMefloquine may increase the QTc-prolonging activities of Tetrabenazine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Tetrabenazine.
MelperoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetrabenazine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrabenazine.
MesoridazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tetrabenazine.
MethadoneMethadone may increase the QTc-prolonging activities of Tetrabenazine.
MethadoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tetrabenazine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tetrabenazine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tetrabenazine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tetrabenazine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tetrabenazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tetrabenazine.
MethsuximideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Methsuximide.
Methylene blueThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tetrabenazine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Tetrabenazine.
MetoprololThe metabolism of Tetrabenazine can be decreased when combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Tetrabenazine.
MetyrosineTetrabenazine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Tetrabenazine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetrabenazine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Tetrabenazine.
MilnacipranThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Milnacipran.
MinaprineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.
MirabegronThe metabolism of Tetrabenazine can be decreased when combined with Mirabegron.
MirtazapineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tetrabenazine.
MoclobemideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Moclobemide.
MoexiprilMoexipril may increase the QTc-prolonging activities of Tetrabenazine.
MolindoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tetrabenazine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Tetrabenazine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.
NabiloneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tetrabenazine.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Tetrabenazine.
NevirapineThe metabolism of Tetrabenazine can be decreased when combined with Nevirapine.
NialamideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Nialamide.
NicardipineThe metabolism of Tetrabenazine can be decreased when combined with Nicardipine.
NilotinibTetrabenazine may increase the QTc-prolonging activities of Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tetrabenazine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tetrabenazine.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Tetrabenazine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Tetrabenazine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tetrabenazine.
OctamoxinThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Octamoxin.
OctreotideOctreotide may increase the QTc-prolonging activities of Tetrabenazine.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Tetrabenazine.
OlanzapineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Olanzapine.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Tetrabenazine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tetrabenazine.
OndansetronThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ondansetron.
OndansetronOndansetron may increase the QTc-prolonging activities of Tetrabenazine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Tetrabenazine.
OrphenadrineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tetrabenazine.
OsanetantThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tetrabenazine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetrabenazine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tetrabenazine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetrabenazine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tetrabenazine.
OxytocinOxytocin may increase the QTc-prolonging activities of Tetrabenazine.
PaliperidonePaliperidone may increase the QTc-prolonging activities of Tetrabenazine.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Tetrabenazine.
ParaldehydeTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Tetrabenazine.
PargylineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pargyline.
ParoxetineThe serum concentration of Tetrabenazine can be increased when it is combined with Paroxetine.
ParoxetineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Tetrabenazine.
PazopanibPazopanib may increase the QTc-prolonging activities of Tetrabenazine.
Peginterferon alfa-2bThe serum concentration of Tetrabenazine can be decreased when it is combined with Peginterferon alfa-2b.
PentamidinePentamidine may increase the QTc-prolonging activities of Tetrabenazine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrabenazine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tetrabenazine.
PerampanelThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Perampanel.
PerflutrenPerflutren may increase the QTc-prolonging activities of Tetrabenazine.
PerospironeThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tetrabenazine.
PhenelzineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Phenelzine.
PheniprazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pheniprazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tetrabenazine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Tetrabenazine.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Phenoxypropazine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tetrabenazine.
PimozidePimozide may increase the QTc-prolonging activities of Tetrabenazine.
PipamperoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pipotiazine.
PirlindoleThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pirlindole.
PivhydrazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pivhydrazine.
PizotifenThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pomalidomide.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Tetrabenazine.
PramipexoleTetrabenazine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tetrabenazine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Tetrabenazine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tetrabenazine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tetrabenazine.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Tetrabenazine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Tetrabenazine.
ProcainamideProcainamide may increase the QTc-prolonging activities of Tetrabenazine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tetrabenazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Promazine.
PromazinePromazine may increase the QTc-prolonging activities of Tetrabenazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Tetrabenazine.
PropafenonePropafenone may increase the QTc-prolonging activities of Tetrabenazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tetrabenazine.
PropericiazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tetrabenazine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Tetrabenazine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tetrabenazine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Tetrabenazine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tetrabenazine.
QuetiapineQuetiapine may increase the QTc-prolonging activities of Tetrabenazine.
QuinidineQuinidine may increase the QTc-prolonging activities of Tetrabenazine.
QuinineQuinine may increase the QTc-prolonging activities of Tetrabenazine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tetrabenazine.
RanolazineThe metabolism of Tetrabenazine can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetrabenazine.
RemoxiprideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetrabenazine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Tetrabenazine.
RisperidoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Risperidone.
RitonavirThe serum concentration of Tetrabenazine can be increased when it is combined with Ritonavir.
RolapitantThe metabolism of Tetrabenazine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Tetrabenazine.
RopiniroleTetrabenazine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Tetrabenazine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetrabenazine.
RotigotineTetrabenazine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tetrabenazine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tetrabenazine.
SafrazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Safrazine.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Tetrabenazine.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Tetrabenazine.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Tetrabenazine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetrabenazine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetrabenazine.
SelegilineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Sertraline.
SertralineThe metabolism of Tetrabenazine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tetrabenazine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Tetrabenazine.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Tetrabenazine.
SorafenibSorafenib may increase the QTc-prolonging activities of Tetrabenazine.
SotalolSotalol may increase the QTc-prolonging activities of Tetrabenazine.
StiripentolThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrabenazine.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Tetrabenazine.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Tetrabenazine.
SulpirideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Sulpiride.
SunitinibSunitinib may increase the QTc-prolonging activities of Tetrabenazine.
SuvorexantThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Suvorexant.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Tetrabenazine.
TapentadolThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tasimelteon.
TelavancinTelavancin may increase the QTc-prolonging activities of Tetrabenazine.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Tetrabenazine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tetrabenazine.
TerbinafineThe serum concentration of Tetrabenazine can be increased when it is combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tetrabenazine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tetrabenazine.
ThalidomideTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tetrabenazine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetrabenazine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tetrabenazine.
ThioproperazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Thioproperazine.
ThioridazineThioridazine may increase the QTc-prolonging activities of Tetrabenazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Tetrabenazine.
TiclopidineThe metabolism of Tetrabenazine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Tetrabenazine.
TipranavirThe serum concentration of Tetrabenazine can be increased when it is combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tetrabenazine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tetrabenazine.
ToloxatoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Toloxatone.
TolterodineTolterodine may increase the QTc-prolonging activities of Tetrabenazine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tetrabenazine.
ToremifeneToremifene may increase the QTc-prolonging activities of Tetrabenazine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetrabenazine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tranylcypromine.
TranylcypromineThe metabolism of Tetrabenazine can be decreased when combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Tetrabenazine.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tetrabenazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Triflupromazine.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Tetrabenazine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tetrabenazine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tetrabenazine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Tetrabenazine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tetrabenazine.
VandetanibTetrabenazine may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Tetrabenazine.
VemurafenibTetrabenazine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Tetrabenazine can be decreased when combined with Venlafaxine.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Tetrabenazine.
VilanterolVilanterol may increase the QTc-prolonging activities of Tetrabenazine.
VilazodoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Vilazodone.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Tetrabenazine.
VorinostatVorinostat may increase the QTc-prolonging activities of Tetrabenazine.
VortioxetineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Tetrabenazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tetrabenazine.
ZiconotideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Zimelidine.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Tetrabenazine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Tetrabenazine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tetrabenazine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tetrabenazine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tetrabenazine.
ZotepineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Zotepine.
ZuclopenthixolZuclopenthixol may increase the QTc-prolonging activities of Tetrabenazine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.
Gene Name:
SLC18A2
Uniprot ID:
Q05940
Molecular Weight:
55712.075 Da
References
  1. Zheng G, Dwoskin LP, Crooks PA: Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J. 2006 Nov 10;8(4):E682-92. [PubMed:17233532 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Kim YS, Shin JH, Hall FS, Linden DJ: Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8. doi: 10.1523/JNEUROSCI.0468-09.2009. [PubMed:19571144 ]
  4. Goland R, Freeby M, Parsey R, Saisho Y, Kumar D, Simpson N, Hirsch J, Prince M, Maffei A, Mann JJ, Butler PC, Van Heertum R, Leibel RL, Ichise M, Harris PE: 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med. 2009 Mar;50(3):382-9. doi: 10.2967/jnumed.108.054866. Epub 2009 Feb 17. [PubMed:19223416 ]
  5. Gros Y, Schuldiner S: Directed evolution reveals hidden properties of VMAT, a neurotransmitter transporter. J Biol Chem. 2010 Feb 12;285(7):5076-84. doi: 10.1074/jbc.M109.081216. Epub 2009 Dec 10. [PubMed:20007701 ]
  6. Wimalasena K: Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev. 2011 Jul;31(4):483-519. doi: 10.1002/med.20187. Epub 2010 Feb 4. [PubMed:20135628 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Poon LH, Kang GA, Lee AJ: Role of tetrabenazine for Huntington's disease-associated chorea. Ann Pharmacother. 2010 Jun;44(6):1080-9. doi: 10.1345/aph.1M582. Epub 2010 May 4. [PubMed:20442355 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-e2 9-reductase activity
Specific Function:
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alp...
Gene Name:
CBR1
Uniprot ID:
P16152
Molecular Weight:
30374.73 Da
References
  1. Jankovic J, Clarence-Smith K: Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011 Nov;11(11):1509-23. doi: 10.1586/ern.11.149. [PubMed:22014129 ]
Comments
comments powered by Disqus
Drug created on October 16, 2007 11:37 / Updated on August 17, 2016 12:24